Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design.
暂无分享,去创建一个
J. Wason | M. Proschan | S. Todd | D. Altman | J. Nicholl | T. Jaki | M. Dimairo | S. Julious | F. Koenig | C. Weir | E. Coates | T. Hamasaki | D. Hind | P. Pallmann | A. Mander | M. Walton | K. Biggs | John A. Scott | Y. Ando | John A Scott | Katie Biggs
[1] Douglas G. Altman,et al. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design , 2019, BMJ.
[2] Lingyun Liu,et al. Adaptive Designs: Results of 2016 Survey on Perception and Use. , 2018, Therapeutic innovation & regulatory science.
[3] A. Sato,et al. Practical characteristics of adaptive design in phase 2 and 3 clinical trials , 2018, Journal of clinical pharmacy and therapeutics.
[4] Jay J H Park,et al. Critical concepts in adaptive clinical trials , 2018, Clinical epidemiology.
[5] Kristian Thorlund,et al. Key design considerations for adaptive clinical trials: a primer for clinicians , 2018, British Medical Journal.
[6] Lisa V. Hampson,et al. Adaptive designs in clinical trials: why use them, and how to run and report them , 2018, BMC Medicine.
[7] A. Kesselheim,et al. Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov , 2018, BMJ Open.
[8] E. Cobo,et al. Are CONSORT checklists submitted by authors adequately reflecting what information is actually reported in published papers? , 2018, Trials.
[9] S. Lewis,et al. Guidelines for the Content of Statistical Analysis Plans in Clinical Trials , 2017, JAMA.
[10] A. Marshall,et al. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines , 2017, BMC Medical Research Methodology.
[11] Victoria Cornelius,et al. Embracing model-based designs for dose-finding trials , 2017, British Journal of Cancer.
[12] S. Heritier,et al. The role of adaptive trial designs in drug development , 2017, Expert review of clinical pharmacology.
[13] Gail Pearson,et al. Efficient design of clinical trials and epidemiological research: is it possible? , 2017, Nature Reviews Cardiology.
[14] F. Bretz,et al. Estimands and Their Role in Clinical Trials , 2017 .
[15] S. Ruberg,et al. Estimands in clinical trials – broadening the perspective , 2017, Statistics in medicine.
[16] Frank Bretz,et al. Estimands: discussion points from the PSI estimands and sensitivity expert group , 2017, Pharmaceutical statistics.
[17] R. Agha,et al. Preferred reporting of case series in surgery; the PROCESS guidelines. , 2016, International journal of surgery.
[18] P. Tugwell,et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials , 2016, British Medical Journal.
[19] David Moher,et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement. , 2016, Journal of clinical epidemiology.
[20] D. Berry,et al. Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project , 2016, Trials.
[21] Rong Tang,et al. Adaptive Design Practice at the Center for Devices and Radiological Health (CDRH), January 2007 to May 2013 , 2016, Therapeutic innovation & regulatory science.
[22] J. Ware,et al. Adaptive Clinical Trial Design: An Overview and Potential Applications in Dermatology. , 2016, The Journal of investigative dermatology.
[23] T. Vos,et al. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement , 2016, PLoS medicine.
[24] M. Dimairo. The Utility of Adaptive Designs in Publicly Funded Confirmatory Trials , 2016 .
[25] M. Dimairo,et al. Adaptive designs undertaken in clinical research: a review of registered clinical trials , 2016, Trials.
[26] E. Russek-Cohen,et al. CBER’s Experience With Adaptive Design Clinical Trials , 2016, Therapeutic innovation & regulatory science.
[27] Frank Bretz,et al. Twenty‐five years of confirmatory adaptive designs: opportunities and pitfalls , 2015, Statistics in medicine.
[28] S. Todd,et al. Cross-sector surveys assessing perceptions of key stakeholders towards barriers, concerns and facilitators to the appropriate use of adaptive designs in confirmatory trials , 2015, Trials.
[29] S. Todd,et al. An Investigation of the Shortcomings of the CONSORT 2010 Statement for the Reporting of Group Sequential Randomised Controlled Trials: A Methodological Systematic Review , 2015, PloS one.
[30] S. Todd,et al. Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials , 2015, Trials.
[31] D. Berry,et al. Reflections on the adaptive designs accelerating promising trials into treatments (ADAPT-IT) process—Findings from a qualitative study , 2015, Clinical research and regulatory affairs.
[32] D. Altman,et al. COS-STAR: a reporting guideline for studies developing core outcome sets (protocol) , 2015, Trials.
[33] G. Guyatt,et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement , 2015, BMJ : British Medical Journal.
[34] K. Lee,et al. Korean translation of the CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials , 2014, Epidemiology and health.
[35] M. Posch,et al. Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency , 2014, Trials.
[36] U. Lorch,et al. Three steps to writing adaptive study protocols in the early phase clinical development of new medicines , 2014, BMC Medical Research Methodology.
[37] J. Oud,et al. Developments in statistical evaluation of clinical trials , 2014 .
[38] B. Feldman,et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. , 2014, Journal of clinical epidemiology.
[39] Yuanxin Rong. Regulations on Adaptive Design Clinical Trials , 2014 .
[40] J. Wathen,et al. Adaptive Design: Results of 2012 Survey on Perception and Use , 2014, Therapeutic innovation & regulatory science.
[41] Shein-Chung Chow,et al. Adaptive clinical trial design. , 2014, Annual review of medicine.
[42] Eberechukwu Onukwugha,et al. Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer , 2014, BMC Medical Research Methodology.
[43] Vladimir Dragalin,et al. Adaptive Clinical Trials: Overview of Phase III Designs and Challenges , 2014, Therapeutic innovation & regulatory science.
[44] T. Jaki. Designing Multi-arm Multi-stage Clinical Studies , 2014 .
[45] David Moher,et al. The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development , 2013, Journal of Medical Case Reports.
[46] David Moher,et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[47] Thomas Jaki,et al. Uptake of novel statistical methods for early-phase clinical studies in the UK public sector , 2013, Clinical trials.
[48] B. Levin,et al. Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop , 2012, Clinical trials.
[49] Paul Hines,et al. Operational Challenges and Solutions with Implementation of an Adaptive Seamless Phase 2/3 Study , 2012, Journal of diabetes science and technology.
[50] C. Coffey,et al. Adaptive trial designs: a review of barriers and opportunities , 2012, Trials.
[51] Shein-Chung Chow,et al. Benefits, challenges and obstacles of adaptive clinical trial designs , 2011, Orphanet journal of rare diseases.
[52] R. Porcher,et al. Adaptive methods: when and how should they be used in clinical trials? , 2011, Therapie.
[53] Robert O'Neill,et al. Adaptive design clinical trials and trial logistics models in CNS drug development , 2011, European Neuropsychopharmacology.
[54] D. Moher,et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2010, BMJ : British Medical Journal.
[55] Christy Chuang-Stein,et al. FDA Draft Guidance on Adaptive Design Clinical Trials: Pfizer's Perspective , 2010, Journal of biopharmaceutical statistics.
[56] D. DeMets,et al. Review of Draft FDA Adaptive Design Guidance , 2010, Journal of biopharmaceutical statistics.
[57] Judith Quinlan,et al. Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development , 2010, Clinical trials.
[58] D. Moher,et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, BMC medicine.
[59] D. Moher,et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials , 2010, Obstetrics and gynecology.
[60] D. Moher,et al. Guidance for Developers of Health Research Reporting Guidelines , 2010, PLoS medicine.
[61] Michael J. Rosenberg. The agile approach to adaptive research , 2010 .
[62] H. Hemilä. Citation bias in the CONSORT comments on blinding , 2010 .
[63] Draft Guidance. Guidance for Industry Adaptive Design Clinical Trials for Drugs and Biologics DRAFT GUIDANCE , 2010 .
[64] Donald A. Berry,et al. Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development , 2009 .
[65] Frank Bretz,et al. Adaptive designs for confirmatory clinical trials , 2009, Statistics in medicine.
[66] B. Muthén,et al. Adaptive designs for randomized trials in public health. , 2009, Annual review of public health.
[67] Shein-Chung Chow,et al. Adaptive design methods in clinical trials – a review , 2008, Orphanet journal of rare diseases.
[68] D. Moher,et al. CONSORT for reporting randomised trials in journal and conference abstracts , 2008, The Lancet.
[69] D. Moher,et al. CONSORT for Reporting Randomized Controlled Trials in Journal and Conference Abstracts: Explanation and Elaboration , 2008, PLoS medicine.
[70] C. Coffey,et al. Adaptive Clinical Trials , 2008, Drugs in R&D.
[71] Vladimir Dragalin,et al. Adaptive Designs: Terminology and Classification , 2006 .
[72] Michael Krams,et al. Implementing Adaptive Designs: Logistical and Operational Considerations , 2006 .
[73] R T O'Neill. FDA's critical path initiative: a perspective on contributions of biostatistics. , 2006, Biometrical journal. Biometrische Zeitschrift.
[74] A. Koch. Confirmatory Clinical Trials with an Adaptive Design , 2006, Biometrical journal. Biometrische Zeitschrift.
[75] A. Gould. How Practical are Adaptive Designs Likely to be for Confirmatory Trials? , 2006, Biometrical journal. Biometrische Zeitschrift.
[76] P Bauer,et al. Application of Adaptive Designs – a Review , 2006, Biometrical journal. Biometrische Zeitschrift.
[77] M. Krams,et al. Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group , 2006, Journal of biopharmaceutical statistics.
[78] Paul Gallo,et al. Operational challenges in adaptive design implementation , 2006, Pharmaceutical statistics.
[79] V. Braun,et al. Using thematic analysis in psychology , 2006 .
[80] O. Keene,et al. Adaptive designs for pivotal trials: discussion points from the PSI Adaptive Design Expert Group , 2006, Pharmaceutical statistics.
[81] W. Brannath,et al. The advantages and disadvantages of adaptive designs for clinical trials. , 2004, Drug discovery today.
[82] D. Altman,et al. STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.
[83] B. Efron. Bootstrap Methods: Another Look at the Jackknife , 1979 .
[84] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.